# Journal of Medicinal Chemistry

# Development and Optimization of Piperidyl-1,2,3-Triazole Ureas as Selective Chemical Probes of Endocannabinoid Biosynthesis

Ku-Lung Hsu,<sup>\*,†,‡,§</sup> Katsunori Tsuboi,<sup>†,‡,§</sup> Landon R. Whitby,<sup>†,‡</sup> Anna E. Speers,<sup>†,‡</sup> Holly Pugh,<sup>‡</sup> Jordon Inloes,<sup>†,‡</sup> and Benjamin F. Cravatt<sup>\*,†,‡</sup>

<sup>†</sup>The Skaggs Institute for Chemical Biology and <sup>‡</sup>Department of Chemical Physiology, The Scripps Research Institute, SR107 10550 North Torrey Pines Road, La Jolla, California 92037, United States.

**(5)** Supporting Information

**ABSTRACT:** We have previously shown that 1,2,3-triazole ureas (1,2,3-TUs) act as versatile class of irreversible serine hydrolase inhibitors that can be tuned to create selective probes for diverse members of this large enzyme class, including diacylglycerol lipase- $\beta$  (DAGL $\beta$ ), a principal biosynthetic enzyme for the endocannabinoid 2-arachidonoyl-glycerol (2-AG). Here, we provide a detailed account of the discovery, synthesis, and structure—activity relationship (SAR) of (2-substituted)-piperidyl-1,2,3-TUs that selectively inactivate DAGL $\beta$  in living systems. Key to success was the use of activity-based protein profiling (ABPP) with broad-spectrum and tailored activity-based probes to guide our medicinal chemistry efforts. We also describe an expanded repertoire of



DAGL-tailored activity-based probes that includes biotinylated and alkyne agents for enzyme enrichment coupled with mass spectrometry-based proteomics and assessment of proteome-wide selectivity. Our findings highlight the broad utility of 1,2,3-TUs for serine hydrolase inhibitor development and their application to create selective probes of endocannabinoid biosynthetic pathways.

# INTRODUCTION

Serine hydrolases (SHs) represent one of the largest and most diverse enzyme families in Nature. The 200+ human members of this enzyme class catalyze the hydrolysis of small-molecule transmitters, lipids, peptides, and proteins<sup>1,2</sup> and have emerged as therapeutic targets for several clinically approved drugs that treat obesity,<sup>3</sup> type 2 diabetes,<sup>3,4</sup> and cognitive disorders.<sup>5</sup> Despite their pervasive roles in biology, most mammalian SHs remain poorly characterized with respect to their biochemical and physiological functions. The development of selective inhibitors to probe the function of individual SHs in living systems would be of great value, but this goal has only been accomplished for a limited number of SH targets.<sup>6–12</sup>

We have shown that 1,2,3-triazole ureas (1,2,3-TUs) serve as a versatile scaffold for developing selective inhibitors of SHs.<sup>8</sup> 1,2,3-TUs inhibit SHs by an irreversible mechanism involving carbamylation of the active-site serine nucleophile (Supporting Information Figure 1). We recently reported the development of potent and selective inhibitors of diacylglycerol lipase- $\beta$ (DAGL $\beta$ ) based on a (2-substituted)-piperidyl (Pip)-1,2,3-TU scaffold.<sup>13,14</sup> DAGL $\beta$  and DAGL $\alpha$  are sequence-related SHs that produce the endocannabinoid, 2-arachidonoylglycerol (2-AG).<sup>15–17</sup> The development of selective, in vivo-active inhibitors targeting DAGL $\beta$  enabled the functional analysis of this enzyme in peritoneal macrophages where it regulates an endocannabinoid–eicosanoid network involved in inflammatory responses.  $^{\rm 13}$ 

Here, we provide a full account of the discovery, synthesis, structure–activity relationship (SAR), and inhibitory activities of (2-substituted)-Pip-1,2,3-TUs that culminated in the discovery of the DAGL $\beta$ -selective inhibitor 11 (KT109) and the dual DAGL $\alpha/\beta$  inhibitor 27 (KT172).<sup>13</sup> We also describe the synthesis of alkyne and biotin-coupled 1,2,3-TUs and their use as tailored activity-based probes for DAGL enzymes. Finally, we show that structurally related (2-phenyl)-Pip-1,2,3-TUs do not inhibit DAGL $\beta$  but maintain potency against the off-target enzyme ABHD6, thus serving as useful negative-control probes for DAGL $\beta$ -related studies, as well as a novel scaffold for developing in vivo-active inhibitors of ABHD6.<sup>18</sup>

# RESULTS

Discovery and Characterization of (2-Substituted)-Pip-1,2,3-TUs as DAGL $\beta$  Inhibitors. As described in our previous studies,<sup>13</sup> we found that the 1,4-regioisomer of (2substituted)-Pip-1,2,3-TUs, such as 2, show enhanced potency for DAGL $\beta$  compared with the corresponding 2,4-regisomer (3) as measured by competitive activity-based protein profiling (ABPP) (Figure 1). ABPP is a chemoproteomic technology



Received: June 17, 2013



**Figure 1.** Characterization of (2-benzyl)-Pip-1,2,3-TU isomers as DAGL $\beta$  inhibitors. The activity of regio- (2 and 3) and stereo- (2a and b) isomers was tested against recombinant DAGL $\beta$  expressed in HEK293T cells and endogenous ABHD6 in mouse Neuro2A neuroblastoma cell proteome using a gel-based competitive ABPP assay. Compounds were preincubated with HEK293T-DAGL $\beta$  membrane (0.3 mg/mL) or Neuro2A (1 mg/mL) proteomes for 30 min at 37 °C prior to treatment with the activity-based probes **38** (HT-01)<sup>13</sup> or fluorophosphonate-rhodamine (FP-Rh), respectively (1  $\mu$ M probe, 30 min), and analysis by gel-based ABPP, where compound activity was measured by reductions in probe-labeling of target SHs. This gel and subsequent fluorescent gels are shown in gray scale.









that utilizes small-molecule probes containing: (1) a reactive group that binds and covalently modifies the active sites of a large number of enzymes that share conserved mechanistic and/or structural features, and (2) a reporter tag, such as a fluorophore or biotin, to facilitate detection, enrichment, and identification of probe-labeled enzymes by SDS-PAGE (gelbased ABPP<sup>19</sup>) and/or quantitative mass spectrometry-based proteomic methods (ABPP-SILAC<sup>8,13</sup>). The regioisomers of (2-substituted)-Pip-1,2,3-TUs arise due to acylation at the N1 or N2 position of the triazole ring during triphosgene-mediated urea formation (Scheme 1). Here, we wanted to determine whether enantiomers of **2** show differences in DAGL $\beta$  potency and selectivity. We resolved racemic **2** into its enantiomers (**2a**  and **b**) using chiral-HPLC and found that **2a** showed ~100-fold greater potency than **2b** against DAGL $\beta$  (Figure 1). We also observed a similar increase in activity against the off-target ABHD6, demonstrating that **2a** provides a similar overall selectivity profile as the racemate. We therefore concluded that the racemate is suitable for biological studies, given that the active enantiomer displayed a similar selectivity profile and only a 2-fold increase in potency over the racemic mixture.

To evaluate whether replacement of the triazole ring with other nitrogenous heterocycles would affect activity against DAGL $\beta$ , we synthesized the triazole (5), pyrazole (8), and imidazole (9) derivatives of the 2-piperidyl-heterocyclic urea scaffold (Scheme 2). We synthesized compound 5 by direct Table 1. Comparison of Activity of (2-Benzyl)-Pip-heterocyclic Urea Derivatives



Scheme 3. Synthesis of (2-Benzyl)-Pip-1,2,3-TUs with 4-Substituted Triazoles



coupling of 4-(4-(trifluoromethoxy)phenyl)-triazole to 2benzylpiperidine and purified the 1,4-regioisomer by preparative TLC. The heterocyclic derivatives were synthesized by triphosgene-mediated coupling of 2-benzylpiperidine with either 4-bromopyrazole or 4-bromoimidazole followed by Suzuki coupling with (4-(trifluoromethoxy)phenyl)boronic acid to generate 8 or 9 as single regioisomers. The activities of compounds 5, 8, and 9 against recombinant DAGL $\beta$  and other SHs in the mouse brain proteome demonstrated that the triazole (5) showed potent activity against DAGL $\beta$  and also inhibited other SHs at higher concentrations, whereas the pyrazole (8) and imidazole (9) derivatives were largely inactive as determined by gel-based ABPP (Table 1). These results indicate that the triazole ring is important for reactivity of (2benzyl)-Pip-1,2,3-TUs with DAGL $\beta$ .

Modifications to the Triazole Ring Enhance Potency and Selectivity of DAGL $\beta$  Inhibitors. We next evaluated substitutions to the 4-position of the triazole ring of DAGL $\beta$ inhibitors. 4-Phenyl-triazoles were synthesized from commercially available alkynes by copper-catalyzed azide–alkyne cycloaddition reaction<sup>20</sup> (CuACC or click chemistry), purified using silica gel chromatography, and coupled to 2-benzyl piperidine to yield compounds 10-13 (Scheme 3). Further coupling of compounds 12 and 13 with phenylboronic acid afforded the biphenyl derivatives 14 and 15. Compound 19 was synthesized using commercially available 4-bromo-1,2,3-triazole coupled to 2-benzyl piperidine under standard conditions to generate a TU intermediate that was then treated with 4-(piperidine-1-carbonyl)-phenylboronic acid in the presence of Pd(II) and  $K_2CO_3$  to provide compound 19 (Scheme 3). Competitive ABPP revealed that compounds 5, 10, and 19 were equipotent against DAGL $\beta$  (Figure 2A), but 5 and 19 showed better selectivity compared to 10 (Figure 2B,C). We next synthesized the biphenyl compound 11 and found that it maintained potency against DAGL $\beta$  and exhibited improved selectivity compared to 5 and 19 (Figure 2A and Table 1). We also compared the activity of isomers of compound 11 that varied in the position of the distal phenyl ring and found that substitutions at the 3- (14) or 2-position (15) reduced potency against DAGL $\beta$  (Figure 2A) or increased off-target activity (Figure 2 and Table 1).

Compound 11 still showed potent activity against ABHD6, as well as low-level cross-reactivity with lipoprotein-associated phospholipase A2 (PLA2G7) at higher concentrations (Figure



**Figure 2.** Potency and selectivity of (2-benzyl)-Pip-1,2,3-TU inhibitors of DAGL $\beta$ . (A) Inhibitory activity of compounds (0.1 or 10  $\mu$ M) against recombinant DAGL $\beta$  expressed by transient transfection in HEK293T cells (DAGL $\beta$ -HEK293T lysates) or recombinant mouse ABHD11 (50 nM) as determined by gel-based competitive ABPP using **38** or FP-Rh, respectively. (B,C) Selectivity of compounds (10 or 1  $\mu$ M) against mouse brain SHs as measured by gel-based competitive ABPP using FP-Rh (B) or **38** (C). The gel-based ABPP assays were performed as described in Figure 1. Assignment of SH enzyme activities in competitive ABPP gels are based on gel migration patterns consistent with past studies.<sup>13,21</sup>

# Scheme 4. Synthesis of Biphenyl Derivatives of (2-Benzyl)-Pip-1,2,3-TUs



2C). To improve the selectivity of compound 11 further, we synthesized derivatives with various substituents added to the distal phenyl ring (Scheme 4). All compounds were synthesized using 2 as a common intermediate for subsequent Suzuki coupling reactions. We tested derivatives with a trifluoromethyl substituent at para- (24), meta- (25), and ortho-positions (26)and found that 26 showed the best potency and selectivity (Figure 3 and Table 2). Substitutions at the para-position of compounds (20 and 24) increased PLA2G7 off-target activity with the exception of larger polar groups (21 and 23). However, these larger polar substitutions also reduced potency against DAGL $\beta$  (Figure 3 and Table 2), and we therefore focused on smaller substituents and found that addition of a hydroxymethyl group at the ortho- (29) but not meta-position (22) improved potency against DAGL $\beta$  (Figure 3). Replacement of the hydroxymethyl with a methoxy substituent (27) eliminated FAAH as an off-target and attenuated PLA2G7 offtarget activity while largely retaining potency against DAGL $\beta$ (Figure 3 and Table 2). Low-level cross-reactivity with monoacylglycerol lipase (MGLL) was, however, observed with compound 27 when tested at 10  $\mu$ M (Figure 3B). These results demonstrate that ortho-substitutions of the biphenyl-triazole ring with small, moderately polar groups

generate  $\text{DAGL}\beta$  inhibitors with excellent activity and selectivity.

In summary, our SAR studies designated compounds 11 and 27 as potent and selective DAGL $\beta$  inhibitors. Both compounds inhibited DAGL $\beta$  in vitro with IC<sub>50</sub> values of 50-80 nM as measured by gel-based ABPP and LC-MS substrate assays.<sup>13</sup> Compounds 11 and 27 showed good selectivity with minimal and complementary cross-reactivity against other SHs with only a single shared off-target, ABHD6 (Figure 2B and 3B). Further studies showed that, while compound 27 was equipotent against DAGL $\alpha$  and DAGL $\beta$ , 11 displayed enhanced potency for DAGL $\beta$  over DAGL $\alpha$  (~60-fold selectivity) as measured by gel-based ABPP,<sup>13</sup> designating these compounds as dual DAGL $\alpha/\beta$  and DAGL $\beta$ -selective inhibitors, respectively. Both compounds displayed excellent potency and selectivity in situ, with near-complete inactivation of DAGL $\beta$  (and ABHD6) in Neuro2A cells at concentrations <50 nM (in situ IC<sub>50</sub> values of 11-14 nM) and negligible cross-reactivity with the 45+ additional SHs detected in this cell line by ABPP-SILAC.<sup>13</sup> Finally, both compounds inactivated DAGL $\beta$  in peritoneal macrophages from mice (1-5 mg kg<sup>-1</sup> of compound, ip).<sup>13</sup>

A Clickable Analogue of Compound 27 Confirms Proteome-Wide Selectivity for DAGL $\beta$ /ABHD6. Our previous competitive ABPP results (both gel- and MS-based



**Figure 3.** Potency and selectivity of biphenyl derivatives of (2-benzyl)-Pip-1,2,3-TUs. (A) Inhibitory activity of compounds (0.1 or 10  $\mu$ M) against recombinant DAGL $\beta$  expressed by transient transfection in HEK293T cells (DAGL $\beta$ -HEK293T lysates) or recombinant mouse ABHD11 (50 nM) as determined by gel-based competitive ABPP using **38** or FP-Rh, respectively. (B,C) The selectivity of compounds (10 or 1  $\mu$ M) against mouse brain SHs was measured using gel-based competitive ABPP with FP-Rh (B) or **38** (C). The gel-based ABPP assays were performed as described in Figure 1. SH activities in gels were assigned as described in Figure 2

$ \begin{array}{c}                                     $					
R =	Compound	DAGLβ % Inhibition (100 nM)	Off-targets (10 µM)		
4-OCF <sub>3</sub>	20	38	KIAA1363, ABHD6, PLA2G7		
3,4-OCH <sub>2</sub> O	21	17	FAAH, ABHD6		
3-CH₂OH	22	11	ABHD6		
4-(piperidine-1-carbonyl)	23	9	ABHD6		
4-CF <sub>3</sub>	24	31	FAAH, KIAA1363, ABHD6, PLA2G7		
3-CF <sub>3</sub>	25	44	FAAH, ABHD6		
2-CF <sub>3</sub>	26	59	ABHD6		
2-OMe	<b>27</b> (KT172)	55	MGLL, ABHD6		
2-OCF <sub>3</sub>	28	59	MGLL, ABHD6, PLA2G7		
2-CH₂OH	29	67	FAAH, MGLL, ABHD6		
2-CI	30	66	ABHD6, PLA2G7, ABHD11		
2-Me	31	63	ABHD6, PLA2G7, ABHD11		

Table 2. Activity of Biphenyl Derivatives of 2-Benzyl Pip-1,2,3-TUs

analyses)<sup>13</sup> showed that the DAGL inhibitors 11 and 27 exhibit excellent selectivity across the SH class but did not address the possibility that these inhibitors may react with other proteins in the proteome. To determine proteome-wide selectivity, we synthesized analogues of 27 (32 and 33; Figure 4A) that bear an alkyne group to serve as a latent affinity handle suitable for modification by reporter tags using copper-catalyzed azide– alkyne cycloaddition chemistry<sup>22</sup> (click chemistry). First, we confirmed that both 32 and 33 retain good inhibitory activity against DAGL $\beta$  and ABHD6 as measured by gel-based competitive ABPP in Neuro2A proteomes (Figure 4B). Next, we treated Neuro2A cells with varying concentrations of 32 or 33 for 1 h. Cells were then lysed and the membrane proteomes conjugated by click chemistry with an azide-Rh tag,<sup>23</sup> separated by SDS-PAGE, and probe-labeled proteins visualized by in-gel fluorescence scanning (Figure 4C). This analysis identified two major protein targets of ~70 and 35 kDa, matching the molecular weights of DAGL $\beta$  and ABHD6, respectively, that could be detected at concentrations of **32** or **33** as low as 10 nM (Figure 4C). Good selectivity for DAGL $\beta$  and ABHD6 was maintained up to ~600 nM of the probes, at which point, a handful of additional probe-labeled proteins were detected. Considering that the parent inhibitors **11** and **27** exhibit in situ activities in the 25–50 nM range,<sup>13</sup> these data argue that both inhibitors maintain good proteome-wide specificity at concentrations required to inhibit DAGL $\beta$  and ABHD6 in cells.

Acyclic Phenethyl-1,2,3-TUs as a Scaffold for Creating DAGL-Tailored Activity-Based Probes. To determine

Article



**Figure 4.** Structure and activity of clickable analogues of compound 27. (A) Chemical structures of clickable probes 32 and 33. (B) In vitro potency of clickable probes against DAGL $\beta$  and ABHD6 in Neuro2A proteome as measured by gel-based competitive ABPP using 38. Neuro2A lysates (1 mg/mL) were incubated with the indicated concentration of compounds (30 min, 37 °C), followed by labeling with 1  $\mu$ M 38 (30 min, 37 °C). (C) Click chemistry ABPP of Neuro2A cells treated in situ with 32 and 33. Neuro2A cells were treated with the indicated concentrations of compound (1 h, 37 °C), lysed and labeled proteins in the membrane fraction were visualized by click chemistry reaction with azide-Rh followed by SDS-PAGE and in-gel fluorescence scanning. Protein bands corresponding to DAGL $\beta$  and ABHD6 are labeled. SH activities in gels were assigned as described in Figure 2

Scheme 5. Synthesis of Acyclic Phenethyl 1,2,3-TUs



whether modifications to the carbamoylating portion of (2substituted)-Pip-1,2,3-TUs would affect potency and selectivity toward DAGL $\beta$ , we synthesized acyclic phenethyl-derivatives following the procedure outlined in Scheme 5. Reductive amination of 2-phenylethanamine with aldehydes resulted in secondary amines that were subsequently coupled with 4-(4-(trifluoromethoxy)phenyl)-triazole to yield compounds 35–37 (Scheme 5). The acyclic phenethyl-1,2,3-TUs still retained potent activity against recombinant DAGL $\beta$  (Figure 5A) with reasonable selectivity against other SHs in the mouse brain proteome as judged by gel-based ABPP (Figure 5B). Depending on the compound, off-target activity was observed for a subset of SHs, including FAAH, KIAA1363, PLA2G7, ABHD6, and an additional unidentified FP-reactive protein (~80 kDa) (Figure 5C and Table 3). These studies demonstrate that acyclic phenethyl-1,2,3-TUs serve as a suitable scaffold to incorporate diverse substituents, including a bulky Boc-group (compound 37), into the DAGL $\beta$  inhibitor scaffold.

We found that 37 served as a versatile intermediate for the design of DAGL-tailored activity-based probes. Initially, we substituted a BODIPY-dye in place of the Boc-group of 37, resulting in the development of the activity-based probe, 38 (Figure 6A), that could detect native DAGL activity in gelbased formats.<sup>13</sup> Compound 38 also provided a complementary probe for other SHs, including PLA2G7, that are difficult to visualize in gel-based assays with the more broad-spectrum



**Figure 5.** Potency and selectivity of acyclic phenethyl-1,2,3-TUs. (A) Inhibitory activity of compounds  $(0.1 \ \mu\text{M})$  against recombinant DAGL $\beta$  expressed by transient transfection in HEK293T cells (DAGL $\beta$ -HEK293T lysates) as determined by gel-based competitive ABPP using **38**. (B,C) Selectivity of compounds against mouse brain SHs as measured by gel-based competitive ABPP using FP-Rh (B) or **38** (C). For the gel-based ABPP assays, proteomes were incubated with compound (0.1, 1, or 10  $\mu$ M) for 30 min at 37 °C followed by reaction with fluorescent ABPP probes (**38** or FP-Rh, 1  $\mu$ M, 30 min, 37 °C). Fluorescent gel images are shown in gray scale. SH activities in gels were assigned as described in Figure 2

Table 3. Activity of Acyclic Phenethyl-1,2,3-TUs



agent FP-Rh.<sup>21</sup> Here, we wanted to determine the full spectrum of SHs targeted by compound 38 in Neuro2A proteomes using the quantitative mass-spectrometry (MS)-based proteomic method ABPP-SILAC.<sup>7,8,13</sup> In brief, light and heavy Neuro2A proteomes (membrane and soluble fractions) were treated with DMSO or 38 (20  $\mu$ M, 30 min), respectively, followed by enrichment of SHs using FP-biotin (10  $\mu$ M, 2 h). As shown in Figure 6B, we observed substantial blockade of FP-biotin labeling for ABHD6, DAGL $\beta$ , DDHD2, and PAFAH2, identifying these SHs as principal targets of 38. The MSbased results helped to assign identities to compound 38labeled SH targets observed in our gel-based analysis, indicating that the ~80-90 kDa doublet observed in both Neuro2A (Figure 6C) and mouse brain proteomes with 38 (Figures 2C, 3C, and 5C) is likely the poorly characterized phospholipase, DDHD2.<sup>24,25</sup> Collectively, these results underscore the value of compound 38 as an activity-based probe for the focused visualization of low-abundance SHs in mammalian proteomes.

**Expansion of DAGL-Tailored Probes to Include Biotin and Alkyne Derivatives of Compound 38.** We next synthesized biotin and alkyne analogues of compound 38 that can be used to directly enrich probe-labeled targets. We incorporated alkyne (39) and biotin (40) functional groups in the 37 precursor using simple amine coupling reactions. Both 39 and 40 showed moderate potency against recombinant DAGL $\alpha$  and DAGL $\beta$  with IC<sub>50</sub> values in the range of 0.4–2  $\mu$ M range (Figure 7). Next, we compared the specificity of 40 with its more broad-spectrum counterpart, FP-biotin<sup>26</sup> using ABPP-SILAC, where probe-treated (heavy) Neuro2A proteomes were compared to DMSO-treated (light) Neuro2A proteomes for SH activities enriched by probes (heavy/light ratios >20). More than 45 SH activities were enriched by FPbiotin (Table 4), which matches previous experiments that inventoried the full-range of SH activities in Neuro2A cells.<sup>13</sup> In contrast, compound 40-enriched samples only contained 16 SHs (Table 4), including all of the established targets of 38: DAGL $\beta$ , ABHD6, DDHD2, and PAFAH2 (Figure 6B). Several additional SH targets were also enriched by compound 40, including ABHD11, ESD, and LYPLAL1 (Table 4). That these enzymes were not identified in competitive ABPP studies with compound 38 (Figure 6B) suggests they are likely lower potency targets of compounds 38 and 40 (or exhibit preferential reactivity with 40).



**Figure 6.** Development of the DAGL-tailored activity-based probe, compound **38**. (A) **37** served as a precursor for coupling of an amine-reactive BODIPY fluorophore to generate **38**. (B) Competitive ABPP-SILAC of SH activities from Neuro2A cells treated in situ with 20  $\mu$ M of **38** for 4 h. Compound **38** inhibited DDHD2, DAGL $\beta$ , ABHD6, and PAFAH2 by  $\geq$ 80% but did not inhibit any of the other detected SHs. Error bars represent mean  $\pm$  SEM of heavy/light ratios for the multiple peptides observed for each enzyme (minimum of three unique peptides per enzyme) in both soluble and membrane fractions. The ABPP-SILAC experiments confirmed (for DAGL $\beta$  and ABHD6) and revealed (for DDHD2) the identity of probe-labeled bands detected by gel-based ABPP in compound **38**-treated Neuro2A membrane proteome ((C) experiment performed as described in Figure 1). Note that PAFAH2 is a soluble enzyme and its signals are likely too low for detection by compound **38** in gel-based ABPP experiments of Neuro2A membrane proteome.



**Figure 7.** Inhibition of recombinant DAGL $\alpha$  and  $\beta$  by **39** and **40**. Inhibitory activity of the alkyne (A) and biotin (B) probes, **39** and **40**, respectively, was measured by competitive ABPP using DAGL-HEK293T membrane lysates. Proteomes were preincubated with varying concentrations of **39** or **40** for 30 min at 37 °C prior to treatment with **38** (1  $\mu$ M, 30 min, 37 °C) and analysis by gel-based ABPP. Both probes blocked **38** labeling of DAGL $\alpha$  and  $\beta$  with IC<sub>50</sub> values ranging from 0.4 to 2  $\mu$ M.

We next compared the subsets of SHs enriched by compound **40** and FP-biotin and asked whether low- or highabundance targets were preferentially identified by each probe, where SH abundance was estimated by spectral counting (Figure 8). Certain high-abundance SHs, such as FASN, are enriched to an equal degree in both sample sets (ratio of log spectral counts ~1; Figure 8). However, other high-abundance SHs, such as PREP, show much lower signals in **40** versus FPbiotin data sets (log spectral count ratio ~0.5; Figure 8). Several additional medium-high abundance SHs (e.g., LYPLA1 and LYPLA2) were also preferentially enriched in FP-biotinexperiments. Conversely, some of the lower abundance targets, like DDHD2, showed substantially higher signals in **40**-compared with FP-biotin-enriched samples (log spectral count ratio ~2; Figure 8). Taken together, these results show that **40** functions as a tailored activity-based probe by providing both enhanced reactivity with low-abundance SHs (DDHD2, PLA2G6, PAFAH2) and attenuated labeling of higher abundance targets (PREP, LYPLA1, and LYPLA2).

Development of a DAGL $\beta$ -Inactive Control Probe That Also Provides a Novel Scaffold for ABHD6 Inhibitors. The ABHD6 cross-reactivity displayed by compounds 11 and

Table	4.	Comparison	of	SHs	Enriched	l by	7 FP	-Biotin	or	40 <sup>4</sup>
-------	----	------------	----	-----	----------	------	------	---------	----	-----------------

S	erine hydrolases enriche	ed in probe vs. no-probe treated samples
	FP-biotin	40
1	ABHD10	ABHD11
2	ABHD11	ABHD6
3	ABHD12	CTSA
4	ABHD13	DAGLB
5	ABHD6	DDHD2
6	ACHE	ESD
7	ACOT2	FASN
8	APEH	LYPLA1
9	BAT5	LYPLA2
10	CTSA	LYPLAL1
11	DAGLB	PAFAH2
12		PLA2G15
13	DPP7	PI A2G6
14	DPP8	PNPLA2
15	DPP9	PPME1
16	FSD	PREP
10	ЕЛАН	T KEI
18	EAM108B1	
10	EAGN	
19		
20		
21		
22		
23		
24	LYPLAT	
25		
26	LYPLALT	
27	NCEH1	
28	PAFAH1B2	
29	PAFAH1B3	
30	PAFAH2	
31	PARL	
32	PGAP1	
33	PLA2G15	
34	PLA2G6	
35	PLAT	
36	PNPLA6	
37	PNPLA7	
38	PNPLA8	
39	PPME1	
40	PPT2	
41	PRCP	
42	PREP	
43	PREPL	
44	QRSL1	
45	RBBP9	
46	SERHI	

<sup>*a*</sup>Light and heavy proteomes were treated with DMSO or probe (10  $\mu$ M of FP-biotin or **40**) for 2 h at room temperature and analyzed by ABPP-SILAC as described in Supporting Information. SHs shown in the table were detected with ratio values >20 in probe/DMSO comparisons (minimum of three unique peptides per protein), denoting selective enrichment in probe-treated proteomes. We also performed a control experiment where we heat-denatured heavy proteomes prior to enrichment with FP-biotin to demonstrate that the detected SHs are enriched in an activity-dependent manner in ABPP-SILAC experiments (Supporting Information Table 1).

27 proved difficult to eliminate with medicinal chemistry. We therefore addressed this issue by synthesizing ABHD6-selective inhibitors that function as negative-control probes for our biological studies. Four separate piperidine analogues were coupled to a 4-bromophenyl-triazole to generate TU intermediates that were then further coupled with substituted phenylboronic acids to produce compounds 46-52 (Scheme 6). We tested the activities of these derivatives using competitive ABPP and found that changing the location of the benzyl group on the piperidine ring from the 2- (27) to 3-(47) or 4-position (49) increased off-target activity (Figure 9A). After determining that the 2-position was optimal, we found that substitution of the 2-benzyl- for a 2-phenyl- (46) or 2-phenethyl-piperidine group (48) dramatically attenuated



**Figure 8.** Comparative analysis of **40**- and FP-biotin-enriched SHs in ABPP-SILAC experiments of Neuro2A proteomes. The signals (log spectral counts) for SH activities that were detected with ratios >20 in probe/DMSO experiments (denoting selective enrichment in probe-treated proteomes; see Table 4 for complete list) and enriched in both FP-biotin and compound **40** data sets are plotted. SHs that show equal enrichment in both probe data sets have log spectral count ratios ~1 (denoted by dashed line). SHs that show preferential enrichment by FP-biotin (red) or **40** (blue) deviate from the slope (log spectral count ratios < or > 1, respectively). The low-abundance SHs DDHD2, PLA2G6, and PAFAH2 show preferential enrichment by compound **40**.

activity against DAGL $\beta$  in comparison with the potent 2benzyl-derivative 27 (Figure 3A, Table 2). To further explore 2phenyl- and 2-phenethyl-scaffolds, we synthesized 50–52 and found that both the 2-phenyl (50) and 2-phenethyl (51) derivatives that lack substituents on the biphenyl-triazole group still retained some activity against DAGL $\beta$  (Figure 9B). In contrast, addition of a *para*-methoxy group produced compound 52 (KT195),<sup>13</sup> which showed a slight reduction in potency for ABHD6 (IC<sub>50</sub> value of 10 nM<sup>13</sup>), but negligible cross-reactivity with DAGL $\beta$  (Figure 9B) or other brain SHs (Figure 9A), and was thus designated as a suitable negativecontrol probe that could be utilized at concentrations similar to those used for compounds 11 and 27 to selectively inhibit ABHD6.

#### CONCLUSION

In summary, we describe the synthesis and SAR of a series of (2-substituted)-Pip-1,2,3-TUs that culminated in discovery of potent, selective, and in vivo-active inhibitors of DAGL $\beta$ .<sup>13</sup> The successful development of DAGL $\beta$ -selective inhibitors highlights the utility of ABPP as not only a universal activity assay for the SH class of enzymes but also adaptable to create tailored activity-based probes to facilitate detection of low-abundance enzymes like DAGL $\beta$ , PLA2G7, and DDHD2. Key to the development of these specialized activity-based probes was the tolerance that DAGL $\beta$  displays for acyclic analogues of the piperidine agents 11 and 27, which permitted the incorporation of diverse reporter tags into the DAGL $\beta$  inhibitor scaffold. Utilizing this synthetic strategy, we were able to generate a suite of fluorescent (38), alkyne (39), and biotin (40) probes that should find broad utility in both gel- and MS-based ABPP studies.

A major finding in our SAR studies was that substitution of mono- for biphenyl triazoles enhanced the selectivity of (2benzyl)-Pip-1,2,3-TUs for DAGL $\beta$ , leading to the development of the optimized DAGL $\beta$  inhibitors, **11** and **27**. We went on to design clickable analogues (**32** and **33**) of optimized DAGL $\beta$ inhibitors, which exhibited good proteome-wide selectivity at Scheme 6. Synthesis of (2-Substituted)-Pip-1,2,3-TUs as Candidate Negative-Control Probes That Inhibit ABHD6



**Figure 9.** Inhibitory activity and selectivity of candidate (2-substituted)-Pip-1,2,3-TU negative-control probes that target ABHD6. (A) Selectivity of control probes against mouse brain SHs as measured by gel-based competitive ABPP using FP-Rh. (B) Inhibitory activity of candidate negative-control probes against DAGL $\beta$ -HEK293T lysates as measured by gel-based competitive ABPP using **38**. Previous studies showed concentration-dependent inhibition of ABHD6 in mouse brain proteomes by **52** (IC<sub>50</sub> = 10 nM) as measured by competitive ABPP.<sup>13</sup> For the gel-based ABPP assays, proteomes were incubated with compound at the indicated concentrations for 30 min at 37 °C followed by reaction with fluorescent ABPP probes (**38** or FP-Rh, 1  $\mu$ M, 30 min, 37 °C). SH activities in gels were assigned as described in Figure 2

concentrations matching those used for the parent inhibitors to inactivate DAGL $\beta$  and ABHD6 in Neuro2A cells. We also discovered from our SAR studies key structural modifications to the DAGL inhibitor scaffold that attenuate DAGL $\beta$  activity while maintaining potency against ABHD6. These studies culminated in the discovery of a (2-phenyl)-Pip-1,2,3-TU, compound **52**, that can serve as a negative-control probe for DAGL $\beta$ -related studies, as well as a novel chemotype for developing next-generation ABHD6-selective inhibitors for functional studies in vivo.<sup>18</sup>

Projecting forward, we believe that 1,2,3-TUs will continue to serve as a useful scaffold for developing selective probes targeting endocannabinoid biosynthetic pathways. With a modest number of analogues, we were able to develop potent and isoform-selective inhibitors capable of inactivating DAGL $\beta$ in vitro and in vivo. Future work will focus on optimizing DAGL inhibitors for improved brain penetrance and CNS activity. Another important goal is the development of DAGL $\alpha$ - selective inhibitors, which should benefit from the availability of gel-based ABPP assays using DAGL-tailored probes (38). Achieving these objectives would create a near-complete set of selective chemical probes for studying 2-AG-mediated endocannabinoid pathways in vivo.

#### EXPERIMENTAL SECTION

**General Synthetic Methods.** All chemicals and reagents that were commercially available were purchased from Sigma-Aldrich, Matrix Scientific, BioBlocks, Combi-Blocks, Maybridge, Fisher, Acros, ChemExper, or Capot Chemicals and used without further purification. Commercial solvents (predried, oxygen-free formulations) were passed through activated alumina columns to obtain dry solvents. Unless noted otherwise, all reactions were performed under a nitrogen atmosphere using oven-baked glassware. Flash chromatography was performed using mesh silica gel (230–400). Analytical thin-layer chromatography (TLC) on glass backed silica gel 60  $F_{254}$  plates was used to monitor reactions. pTLC on silica gel 60  $F_{254}$  plates or flash chromatography on 40–60 MYM mesh silica gel were used to purify

reactions. <sup>1</sup>H NMR and spectra were recorded in  $\text{CDCl}_3$  on a Varian Mercury-300 spectrometer, a Varian Inova-400, Bruker DRX-500, or a Bruker DRX-600 spectrometer, and referenced to trimethylsilane (TMS). Chemical shifts were reported in ppm relative to TMS and *J* values were reported in Hz. High resolution mass spectrometry (HRMS) experiments were performed at The Scripps Research Institute Mass Spectrometry Core on an Agilent mass spectrometer using electrospray ionization-time-of-flight (ESI-TOF). The purity of final compounds were determined to be  $\geq$ 95% by HPLC analysis (Agilent 1100 LC/MS).

Hex-5-yn-1-yl (5-(N-Phenethyl-4-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazole-1-carboxamido)pentyl)carbamate (**39**). A solution of 5-hexyn-1-ol (10 mg, 0.10 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was treated with triphosgene (30 mg, 0.10 mmol, 1.0 equiv) and pyridine (8  $\mu$ L, 0.10 mmol, 1.0 equiv), and the mixture was stirred for 30 min at 4 °C. The mixture was poured into H<sub>2</sub>O and extracted with ethyl acetate. The organic layer was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was dissolved in THF (1 mL), and Boc-deprotected urea 37<sup>13</sup> (7 mg, 14  $\mu$ mol) and iPr<sub>2</sub>NEt (10  $\mu$ L) were added to the solution. After stirring for 1 h at room temperature, the mixture was poured into H<sub>2</sub>O and extracted with ethyl acetate. The organic layer was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. pTLC (ethyl acetate:hexane = 1:3) afforded **39** (8 mg, 98%).

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.42–7.80 (m, 3H), 7.40–7.10 (m, 7H), 4.70 (br, 1H), 4.15–3.50 (m, 6H), 3.25–2.95 (m, 4H), 2.22 (td, 2H, J = 7.0, 2.6 Hz), 1.95 (t, 1H, J = 2.6 Hz), 1.65–1.20 (m, 10H). HRMS calculated for C<sub>30</sub>H<sub>35</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup> 586.2636, found 586.2633.

*N*-(5-(5-(2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)pentyl)-*N*-phenethyl-4-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazole-1-carboxamide (**40**). A solution of the urea 37 (13 mg, 23  $\mu$ mol) in CH<sub>2</sub>Cl<sub>2</sub> (0.6 mL) was treated with 4N HCl–dioxane (0.6 mL), and the mixture was stirred for 3 h at room temperature. The solvent was evaporated and the residue was dissolved in DMF (1 mL). iPr<sub>2</sub>NEt (12  $\mu$ L, 69  $\mu$ mol, 3.0 equiv) and biotin-NHS (8 mg, 23  $\mu$ mol, 1.0 equiv) was added to the solution, and the mixture was stirred for 2 h at room temperature. The organic layer was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. Et<sub>2</sub>O (1 mL) was added and the mixture was sonicated. The supernatant was removed, and this procedure was repeated twice to afford **40** (10 mg, 63%).

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  8.43–7.80 (m, 3H), 7.35–7.05 (m, 7H), 6.25–6.03 (m, 2H), 5.30 (s, 1H), 4.48 (m, 1H), 4.29 (m, 1H), 4.00–3.50 (m, 4H), 3.30–2.80 (m, 6H), 2.70 (d, 1H, *J* = 13.0 Hz), 2.18 (t, *J* = 7.4 Hz), 1.80–1.20 (m, 10H). HRMS calculated for C<sub>33</sub>H<sub>41</sub>F<sub>3</sub>N<sub>7</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 688.2887, found 688.2883.

**Materials for Biological Experiments.** FP-rhodamine,<sup>26</sup> FPbiotin,<sup>26,27</sup> and **38**<sup>13</sup> were synthesized as previously described. Neuro2A and HEK293T cells were purchased from ATCC.

Cell Culture and Preparation of Cell Line Proteomes. Neuro2A and HEK293T cells were grown in DMEM supplemented with 10% fetal bovine serum at 37 °C with 5% CO<sub>2</sub>. For in vitro experiments, cells were grown to 80–90% confluency, washed twice with cold PBS (pH 7.5), and scraped. Cell pellets were then isolated by centrifugation at 1400g for 3 min at 4 °C. The pellets were resuspended in 500  $\mu$ L of cold PBS (pH 7.5), sonicated, and centrifuged at 100000g for 45 min to generate soluble and membrane fractions. Mouse DAGL $\alpha$  and DAGL $\beta$  were transiently overexpressed in HEK293T cells as previously described.<sup>13</sup> Total protein concentration of membrane and soluble fractions was determined using a protein assay kit (Bio-Rad). Samples were stored at -80 °C until use.

**Preparation of Mouse Brain and Liver Proteomes.** Brains and livers from C57Bl/6 mice were Dounce-homogenized in PBS, pH 7.5, followed by a low-speed spin (1400g, 5 min) to remove debris. The supernatant was then centrifuged (100000g, 45 min) to generate the cytosolic fraction in the supernatant and the membrane fraction as a pellet. The pellet was washed and resuspended in PBS buffer by

sonication. The total protein concentration in each fraction was determined using a protein assay kit (Bio-Rad). Samples were stored at -80 °C until further use.

**Gel-Based Competitive ABPP.** Gel-based competitive ABPP experiments were performed following previously described protocols. <sup>13,28,29</sup> Proteomes (1 mg/mL) were pretreated with compounds at indicated concentrations (30 min, 37 °C) followed by labeling with either FP-rhodamine or 38 (1  $\mu$ M final concentration) in a 50  $\mu$ L total reaction volume. After 30 min or 1 h at 37 °C, the FP-rhodamine- or 38-labeled reactions, respectively, were quenched with SDS-PAGE loading buffer. After separation by SDS-PAGE (10% acrylamide), samples were visualized by in-gel fluorescence scanning using a flatbed fluorescent scanner (Hitachi FMBio IIe). To measure recombinant DAGL $\beta$  activity, proteomes were diluted to 0.3 mg/mL in assay buffer (50 mM HEPES, pH 7.2, 100 mM NaCl, 5 mM CaCl<sub>2</sub>, 0.1% v/v TX-100, 10% v/v DMSO) and subjected to ABPP analysis as described above.

**Cycloaddition Reactions with the Clickable Probes 32 and 33.** Click chemistry was performed following previously described protocols.<sup>30</sup> For in vitro experiments, membrane proteomes (1 mg/ mL in PBS) were incubated with DMSO or varying concentrations of compound **32** or **33** (3 nM to 10  $\mu$ M) at 37 °C for 30 min prior to incubation with **38** (1  $\mu$ M) for 30 min. For in situ experiments, Neuro2A cells were incubated with DMSO, **32** or **33** (10 nM to 25  $\mu$ M clickable probes) for 1 h at 37 °C, lysed, and membrane fractions isolated for click-chemistry. The alkyne-labeled membrane proteomes (1 mg/mL in PBS) were then incubated with rhodamine-azide (50  $\mu$ M), followed by TCEP (1 mM), ligand (100  $\mu$ M), and CuSO<sub>4</sub> (1 mM). After 1 h at 25 °C, reactions were analyzed by SDS-PAGE and in-gel fluorescence scanning.

Competitive ABPP-SILAC. Neuro2A cells were grown for 10 passages in either light or heavy SILAC DMEM medium supplemented with 10% (v/v) dialyzed FCS and 2 mM L-glutamine. The light medium was supplemented with 100  $\mu$ g/mL L-arginine and 100  $\mu$ g/mL L-lysine. Heavy medium was supplemented with 100  $\mu$ g/ mL  $[{}^{13}C_6{}^{15}N_4]$ -L-arginine and 100  $\mu$ g/mL  $[{}^{13}C_6{}^{15}N_2]$ -L-lysine. The heavy cells (in 10 mL medium) were treated with test compound, and light cells were treated with DMSO for 4 h at 37 °C. Cells were washed with PBS  $(2\times)$ , harvested, and lysed by sonication in DPBS. Membrane and soluble proteomes were isolated as described above and adjusted to a final concentration of 2.0 mg/mL and labeled with 10  $\mu$ M FP-biotin (500  $\mu$ L total reaction volume) for 2 h at 25 °C. After incubation, light and heavy proteomes were mixed in 1:1 ratio, and excess FP-biotin removed by CHCl<sub>3</sub>/MeOH extraction. To the light and heavy mixed proteomes (1 mL volume), 2 mL of CH<sub>3</sub>OH, 0.5 mL of CHCl<sub>3</sub>, and 1.5 mL of H<sub>2</sub>O was added and the mixtures vortexed and centrifuged at 1400g for 3 min. The top (aqueous) and bottom (organic) layers were removed, and 600  $\mu$ L of MeOH was added to the protein interface, which was subsequently transferred to a microfuge tube. Next, 150 µL of CHCl<sub>3</sub> and 600 µL of H<sub>2</sub>O were added, vortexed, and centrifuged as described above. The top and bottom layers were removed and the protein interface sonicated in 600  $\mu L$  of MeOH and then centrifuged at 14000 rpm for 5 min to pellet protein. The MeOH was removed and pellet resuspended in 6 M urea/25 mM ammonium bicarbonate. Samples were then reduced with 10 mM DTT for 15 min (65 °C) and alkylated with 40 mM iodoacetamide for 30 min at 25 °C in the dark. Afterward, samples were treated with SDS (2% final, 5 min) and biotinylated proteins enriched with avidin beads (50 µL beads; conditions, 1 h, 25 °C, 0.5% SDS in PBS). The beads were washed three times with 1% SDS in PBS followed by three washes with PBS. The urea concentration was reduced to 2 M with 2× volume DPBS. On-bead digestions were performed for 12 h at 37 °C with sequence-grade modified trypsin (Promega; 2  $\mu$ g) in the presence of 2 mM CaCl<sub>2</sub>. Peptide samples were acidified to a final concentration of 5% (v/v) formic acid and stored at -80 °C prior to analysis. LC-MS/MS analysis of ABPP-SILAC samples were performed as previously described.<sup>7,8,13</sup>

# ASSOCIATED CONTENT

#### **S** Supporting Information

Supplemental methods, synthetic procedures and characterization of 1,2,3-triazole ureas, HRMS data, chiral separation of compound **2**, and supplemental figures. This material is available free of charge via the Internet at http://pubs.acs.org.

#### AUTHOR INFORMATION

#### Corresponding Authors

\*For K.L.H.: phone, 858-784-8636; E-mail, kenhsu@scripps. edu.

\*For B.F.C.: phone, 858-784-8633; E-mail, cravatt@scripps. edu.

#### **Author Contributions**

<sup>§</sup>These authors contributed equally to this work

#### Notes

The authors declare the following competing financial interest(s): Dr. Cravatt is a cofounder and scientific advisor to Abide Therapeutics, a biotechnology company interested in developing SH inhibitors as therapeutics.

#### ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health Grants DA017259 (B.F.C.), DA033760 (B.F.C.), and MH084512 (B.F.C.), a Hewitt Foundation Postdoctoral Fellowship (K.L.H.), the Skaggs Institute for Chemical Biology, and Dainippon Sumitomo Pharma (K.T.)

# ABBREVIATIONS USED

SH, serine hydrolase; Pip-1,2,3-TU, piperidyl-1,2,3-triazole urea; ABPP, activity-based protein profiling; CuAAC, coppercatalyzed azide alkyne cycloaddition; SILAC, stable isotope labeling by amino acids in cell culture; FP-Rh, fluorophosphonate-rhodamine

#### REFERENCES

(1) Simon, G. M.; Cravatt, B. F. Activity-based proteomics of enzyme superfamilies: serine hydrolases as a case study. *J. Biol. Chem.* **2010**, 285, 11051–11055.

(2) Long, J. Z.; Cravatt, B. F. The metabolic serine hydrolases and their functions in mammalian physiology and disease. *Chem. Rev.* **2011**, *111*, 6022–6063.

(3) Henness, S.; Perry, C. M. Orlistat: a review of its use in the management of obesity. *Drugs* **2006**, *66*, 1625–1656.

(4) Thornberry, N. A.; Weber, A. E. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. *Curr. Top. Med. Chem.* **2007**, *7*, 557–568.

(5) Racchi, M.; Mazzucchelli, M.; Porrello, E.; Lanni, C.; Govoni, S. Acetylcholinesterase inhibitors: novel activities of old molecules. *Pharmacol. Res.* **2004**, *50*, 441–451.

(6) Bachovchin, D. A.; Cravatt, B. F. The pharmacological landscape and therapeutic potential of serine hydrolases. *Nature Rev. Drug Discovery* **2012**, *11*, 52–68.

(7) Bachovchin, D. A.; Mohr, J. T.; Speers, A. E.; Wang, C.; Berlin, J. M.; Spicer, T. P.; Fernandez-Vega, V.; Chase, P.; Hodder, P. S.; Schurer, S. C.; Nomura, D. K.; Rosen, H.; Fu, G. C.; Cravatt, B. F. Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. *Proc. Natl. Acad. Sci. U. S. A.* **2011**, *108*, 6811–6816.

(8) Adibekian, A.; Martin, B. R.; Wang, C.; Hsu, K. L.; Bachovchin, D. A.; Niessen, S.; Hoover, H.; Cravatt, B. F. Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. *Nature Chem. Biol.* **2011**, *7*, 469–478.

(9) Long, J. Z.; Li, W.; Booker, L.; Burston, J. J.; Kinsey, S. G.; Schlosburg, J. E.; Pavon, F. J.; Serrano, A. M.; Selley, D. E.; Parsons, L. H.; Lichtman, A. H.; Cravatt, B. F. Selective blockade of 2arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. *Nature Chem. Biol.* **2009**, *5*, 37–44.

(10) Chang, J. W.; Nomura, D. K.; Cravatt, B. F. A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. *Chem. Biol.* **2011**, *18*, 476–484.

(11) Åhn, K.; Smith, S. E.; Liimatta, M. B.; Beidler, D.; Sadagopan, N.; Dudley, D. T.; Young, T.; Wren, P.; Zhang, Y.; Swaney, S.; Van Becelaere, K.; Blankman, J. L.; Nomura, D. K.; Bhattachar, S. N.; Stiff, C.; Nomanbhoy, T. K.; Weerapana, E.; Johnson, D. S.; Cravatt, B. F. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. *J. Pharmacol. Exp. Ther.* **2011**, 338, 114–124.

(12) Zuhl, A. M.; Mohr, J. T.; Bachovchin, D. A.; Niessen, S.; Hsu, K. L.; Berlin, J. M.; Dochnahl, M.; Lopez-Alberca, M. P.; Fu, G. C.; Cravatt, B. F. Competitive activity-based protein profiling identifies aza-beta-lactams as a versatile chemotype for serine hydrolase inhibition. J. Am. Chem. Soc. 2012, 134, 5068-5071.

(13) Hsu, K. L.; Tsuboi, K.; Adibekian, A.; Pugh, H.; Masuda, K.; Cravatt, B. F. DAGLbeta inhibition perturbs a lipid network involved in macrophage inflammatory responses. *Nature Chem. Biol.* **2012**, *8*, 999–1007.

(14) Hsu, K. L.; Tsuboi, K.; Speers, A. E.; Brown, S. J.; Spicer, T.; Fernandez-Vega, V.; Ferguson, J.; Cravatt, B. F.; Hodder, P.; Rosen, H. Optimization and characterization of a triazole urea inhibitor for diacylglycerol lipase beta (DAGL- $\beta$ ). In *Probe Reports from the NIH Molecular Libraries Program* [*Internet*]; National Center for Biotechnology Information: Bethesda, MD, **2012**; (updated Feb 25 2013).

(15) Bisogno, T.; Howell, F.; Williams, G.; Minassi, A.; Cascio, M. G.; Ligresti, A.; Matias, I.; Schiano-Moriello, A.; Paul, P.; Williams, E. J.; Gangadharan, U.; Hobbs, C.; Di Marzo, V.; Doherty, P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. *J. Cell Biol.* **2003**, *163*, 463–468.

(16) Gao, Y.; Vasilyev, D. V.; Goncalves, M. B.; Howell, F. V.; Hobbs, C.; Reisenberg, M.; Shen, R.; Zhang, M. Y.; Strassle, B. W.; Lu, P.; Mark, L.; Piesla, M. J.; Deng, K.; Kouranova, E. V.; Ring, R. H.; Whiteside, G. T.; Bates, B.; Walsh, F. S.; Williams, G.; Pangalos, M. N.; Samad, T. A.; Doherty, P. Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice. J. Neurosci. 2010, 30, 2017–2024.

(17) Tanimura, A.; Yamazaki, M.; Hashimotodani, Y.; Uchigashima, M.; Kawata, S.; Abe, M.; Kita, Y.; Hashimoto, K.; Shimizu, T.; Watanabe, M.; Sakimura, K.; Kano, M. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. *Neuron* **2010**, *65*, 320–327.

(18) Hsu, K. L.; Tsuboi, K.; Chang, J. W.; Whitby, L. R.; Speers, A. E.; Pugh, H.; Cravatt, B. F. Discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in vivo-active inhibitors of alpha/beta-hydrolase domain containing 6 (ABHD6). *J. Med. Chem.* **2013** DOI: 10.1021/jm400899c.

(19) Jessani, N.; Liu, Y.; Humphrey, M.; Cravatt, B. F. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. *Proc. Natl. Acad. Sci. U. S. A.* **2002**, *99*, 10335–10340.

(20) Kalisiak, J.; Sharpless, K. B.; Fokin, V. V. Efficient Synthesis of 2-Substituted-1,2,3-triazoles. *Org. Lett.* **2008**, *10*, 3171–3174.

(21) Nagano, J. M.; Hsu, K. L.; Whitby, L. R.; Niphakis, M. J.; Speers, A. E.; Brown, S. J.; Spicer, T.; Fernandez-Vega, V.; Ferguson, J.; Hodder, P.; Srinivasan, P.; Gonzalez, T. D.; Rosen, H.; Bahnson, B. J.; Cravatt, B. F. Selective inhibitors and tailored activity probes for lipoprotein-associated phospholipase A(2). *Bioorg. Med. Chem. Lett.* **2013**, *23*, 839–843.

(22) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective "Ligation" of Azides and Terminal Alkynes. *Angew. Chem., Int. Ed.* **2002**, *41*, 2596–2599.

(23) Speers, A. E.; Cravatt, B. F. Profiling enzyme activities in vivo using click chemistry methods. *Chem. Biol.* **2004**, *11*, 535–546.

(24) Schuurs-Hoeijmakers, J. H.; Geraghty, M. T.; Kamsteeg, E. J.; Ben-Salem, S.; de Bot, S. T.; Nijhof, B.; van de Vondervoort, I. I. G. M.; van der Graaf, M.; Nobau, A. C.; Otte-Holler, I.; Vermeer, S.; Smith, A. C.; Humphreys, P.; Schwartzentruber, J.; Ali, B. R.; Al-Yahyaee, S. A.; Tariq, S.; Pramathan, T.; Bayoumi, R.; Kremer, H. P. H.; van de Warrenburg, B. P.; van den Akker, W. M.; Gilissen, C.; Veltman, J. A.; Janssen, I. M.; Vulto-van Silfhout, A. T.; van der Velde-Visser, S.; Lefeber, D. J.; Diekstra, A.; Erasmus, C. E.; Willemsen, M. A.; Vissers, L. E.; Lammens, M.; van Bokhoven, H.; Brunner, H. G.; Wevers, R. A.; Schenck, A.; Al-Gazali, L.; de Vries, B. B. A.; de Brouwer, A. P. M. Mutations in DDHD2, encoding an intracellular phospholipase A(1), cause a recessive form of complex hereditary spastic paraplegia. *Am. J. Hum. Genet.* **2012**, *91*, 1073–1081.

(25) Nakajima, K.; Sonoda, H.; Mizoguchi, T.; Aoki, J.; Arai, H.; Nagahama, M.; Tagaya, M.; Tani, K. A novel phospholipase A1 with sequence homology to mammalian Sec23p-interacting protein, p125. *J. Biol. Chem.* **2002**, *277*, 11329–11335.

(26) Liu, Y.; Patricelli, M. P.; Cravatt, B. F. Activity-based protein profiling: the serine hydrolases. *Proc. Natl. Acad. Sci. U. S. A.* **1999**, *96*, 14694–14699.

(27) Kidd, D.; Liu, Y.; Cravatt, B. F. Profiling serine hydrolase activities in complex proteomes. *Biochemistry* **2001**, *40*, 4005–4015.

(28) Bachovchin, D. A.; Ji, T.; Li, W.; Simon, G. M.; Blankman, J. L.; Adibekian, A.; Hoover, H.; Niessen, S.; Cravatt, B. F. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 20941–20946.

(29) Jessani, N.; Niessen, S.; Wei, B. Q.; Nicolau, M.; Humphrey, M.; Ji, Y.; Han, W.; Noh, D. Y.; Yates, J. R., III; Jeffrey, S. S.; Cravatt, B. F. A streamlined platform for high-content functional proteomics of primary human specimens. *Nature Methods* **2005**, *2*, 691–697.

(30) Speers, A. E.; Adam, G. C.; Cravatt, B. F. Activity-Based Protein Profiling in Vivo Using a Copper(I)-Catalyzed Azide-Alkyne [3 + 2] Cycloaddition. J. Am. Chem. Soc. **2003**, 125, 4686–4687.